(Total Views: 419)
Posted On: 11/04/2024 11:02:28 PM
Post# of 155366
Quote:
A surrogate endpoint....
The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint.
In the case of mssCRC and Alzheimer's it would be proof in clinical endpoints backed up by surrogate endpoints. What would hinder mssCRC is unmet need.
(3)
(0)
